Kowa Company, Ltd.
Kowa Company, Ltd.
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pemafibrate for Symptomatic ICAS RCT | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hyperlipidemia, hypertriglyceridemia, metabolic disease, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-08-03 | NCT07562178 | |
| A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Recruiting | Phase 4 | 2026-07-13 | NCT07634484 | |
| Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 2 | 2022-07-22 | NCT05469659 |